(Q44383401)

2 December 2017

title

Clinical and psychological aspects of restless legs syndrome in uremic patients on hemodialysis (English)

1 reference

2 December 2017

main subject

restless legs syndrome

1 reference

1 reference

Jiro Takaki

1

1 reference

2 December 2017

Tadahiro Nishi

2

1 reference

2 December 2017

Masaomi Nangaku

3

1 reference

2 December 2017

Hiromi Shimoyama

4

1 reference

2 December 2017

Toshio Inada

5

1 reference

2 December 2017

Norimasa Matsuyama

6

1 reference

2 December 2017

Hiroaki Kumano

7

1 reference

2 December 2017

Tomifusa Kuboki

8

1 reference

2 December 2017

publication date

1 April 2003

1 reference

American Journal of Kidney Diseases

2 December 2017

published in

1 reference

2 December 2017

volume

41

1 reference

2 December 2017

issue

4

1 reference

2 December 2017

page(s)

833-839

1 reference

Restless legs syndrome: clinical features and treatment

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Clinical and biochemical findings in uremic patients with and without restless legs syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

An overview of levodopa in the management of restless legs syndrome in a dialysis population: pharmacokinetics, clinical trials, and complications of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Restless legs syndrome in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Possible relation between restless legs and anaemia in renal dialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

The hospital anxiety and depression scale

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

A Coefficient of Agreement for Nominal Scales

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Time-limit tests: estimating their reliability and degree of speeding

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Symptoms in hemodialysis patients and their relationship with biochemical and demographic parameters.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Prevalence of sleep disturbances in chinese patients with end-stage renal failure on continuous ambulatory peritoneal dialysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Restless legs syndrome (RLS) in uremic patients is related to the frequency of hemodialysis sessions

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Restless legs syndrome: a review of clinical and pathophysiologic features

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Intrarenal serotonin, dopamine, and phosphate handling in remnant kidneys

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Dopamine enhances the phosphaturic effect of PTH during acute respiratory alkalosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

gamma-L-glutamyl-L-DOPA inhibits Na(+)-phosphate cotransport across renal brush border membranes and increases renal excretion of phosphate

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Restless legs syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Consequences of hyperphosphatemia and elevated levels of the calcium-phosphorus product in dialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Hyperphosphatemia in end-stage renal disease patients: pathophysiological consequences

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

EEG mapping in patients with restless legs syndrome as compared with normal controls

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Restless legs syndrome in 218 patients: associated disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and Morbidity in Augsburg Elderly.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD): acute placebo-controlled sleep laboratory studies with clonazepam

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Paroxetine: an update of its use in psychiatric disorders in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Placebo-controlled study of gabapentin treatment of panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Treatment of social phobia with gabapentin: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Selective serotonin receptor uptake inhibitors can reduce restless legs symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Treatment of idiopathic restless legs syndrome (RLS) with gabapentin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Restless leg syndrome exacerbated by sertraline

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

The treatment of the restless legs syndrome with clonazepam: a prospective controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Harnessing placebo effects in health care

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

The moderator–mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Coping and personality: third time's the charm?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

Coping as a personality process: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900031-3

7 January 2021

10.1016/S0272-6386(03)00031-3

Identifiers

DOI

1 reference

2 December 2017

1 reference